Please assess the completion status of the following clinical trial:

Trial Title: Variability of the Autonomic Nervous System (ANS) During Cluster Headache (CH).

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 years of age~* Affiliated or entitled to a Social Security scheme~* Resident in the territories of the hospital grouping of Loire territory (located less than 50 km away)~* Whose diagnosis of episodic or chronic Cluster Headache (CH) has been confirmed according to International Classification of Headache Disorders (ICHD)- 3 criteria~* With a regular sinus rhythm and heart rate~Exclusion Criteria:~* Conditions contraindicating the use of injectable sumatriptan~* Conditions likely to affect the Autonomic Nervous System (ANS): dysautonomic sensory neuropathies, sleep apnea syndrome, etc.~* Cognitive or language disorders that may interfere with pain assessment and seizure follow-up.~* Patients taking treatments that may modify the Autonomic Nervous System (ANS): catecholamine (adrenaline, noradrenaline, dopamine), B-stimulants (isoprenaline, dobutamine, dopexamine, salbutamol, terbutaline, fenoterol, orciprenaline, clenbuterol, salmeterol, formoterol), B-blockers, alpha-stimulants (midodrine, alpha-methyl-dopa, clonidine, rilmenidine, moxonidine), alpha-blockers (phentolamine, prazosin, urapidil), amphetamine, tyramine, ephedrine, selegiline, cocaine, imipramine.~* Impossibility to submit to the medical follow-up of the program for geographical, social or psychological reasons.~* Patient deprived of liberty or under guardianship.~* Patient with preventive background treatment of Cluster Headache (CH).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Cluster Headache (CH) (Type: None): Patients with Cluster Headache (CH) will be included. They will have a Holter electrocardiogram during 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).